tirzepatide health canada approval FDA Grants a New Indication for Obesity Management Health Canada approves Mounjaro® (tirzepatide)

Both formulations are approved for people with obesity (BMI greater than 30) or excess weight (BMI greater than 27) who also have at least one other weight-related health condition, such as type 2 diabetes, high blood pressure, or high cholesterol

In these cases, the medication might unmask or worsen an existing issue, rather than causing a brand-new permanent condition [4] [16]

Delayed Gastric Emptying More Likely, Gallstones and Ileus Less Likely for Diabetic Patients on GLP-1 Medications Compared to Diabetics on Other Treatments

[5] [1] Other important safety considerations include risks of pancreatitis, gallbladder disease, acute kidney injury, hypersensitivity reactions, and caution in patients with severe gastrointestinal disease

Select the vial strength and open the linked COA record where available before placing an order